Mayo Clinic Laboratory and Pathology Research Roundup: Feb. 12

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery

Predicting oncologic outcomes is important for patient counseling, clinical trial design, and biomarker study testing. Mayo Clinic researchers conducted a study to develop prognostic models for progression-free and cancer-specific survival in patients with clear cell renal cell carcinoma (ccRCC), papillary RCC (papRCC), and chromophobe RCC (chrRCC). Using a large institutional experience, researchers generated specific prognostic models for oncologic outcomes in ccRCC, papRCC, and chrRCC that rely on features previously shown-and validated-to be associated with survival. These updated models should inform patient prognosis, biomarker design, and clinical trial enrollment. The study was published in European Urology.

Published to PubMed This Week

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.